iShares MSCI Japan ETF vs Regeneron Pharmaceuticals Inc — how do they compare? iShares MSCI Japan ETF trades at $96.35, while Regeneron Pharmaceuticals Inc trades at $796.38 (market cap $83.19B). The key difference: Regeneron Pharmaceuticals Inc pays a 0.47% dividend while iShares MSCI Japan ETF pays none. Which is the better fit depends on your goals.
| EWJ | REGN | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $96.97 | $812.27 |
52-Week Low | $77.93 | $555.51 |
Market Cap | — | $83.19B |
Enterprise Value | — | $77.90B |
Dividend Yield | — | 0.47% |
Signals from Pluang's Aura AI — not financial advice
EWJ, the iShares MSCI Japan ETF, trades at $96.90, up 1.84% with a bullish technical signal from moving averages. Recent U.S.-Japan yen intervention and domestic economic stimulus efforts, including a food tax cut, are key drivers. The ETF's RSI_6 at 90.64 indicates overbought conditions, while support and resistance cluster near $96-$97.
Outlook is cautiously optimistic due to policy support and export benefits from yen strength, but risks include inflation pressures and tech sector volatility. The dividend of $0.50 scheduled for June 2026 adds income appeal, though current financial ratios are undisclosed, requiring scrutiny of underlying holdings.
Regeneron Pharmaceuticals (REGN) trades at $784.36, up 1.59% today, with a bullish technical signal from moving averages but overbought RSI readings. The company shows strong profitability with a net income margin of 27.86% and has beaten EPS estimates in recent quarters. However, multiple class-action lawsuits filed in August 2026 allege inadequate clinical-trial risk disclosures, creating investor uncertainty amid solid financial performance.
Outlook remains supported by earnings momentum and analyst buy ratings, but legal risks and high valuation multiples pose near-term headwinds. Investment opportunity hinges on legal resolution and sustained drug pipeline success, while risks include trial setbacks and regulatory scrutiny.
Trailing returns across standard periods
Latest headlines on both assets
EWJ tracks the MSCI Japan Index, providing broad exposure to over 180 large and mid-cap companies in Japan. It is the most established and liquid vehicle for accessing the Japanese equity market, featuring a diversified portfolio across industrials, consumer discretionary, and financial sectors.
Read more on EWJ →Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →